Access Pharmaceuticals of Dallas Reports First Quarter 2013 Results

Access Pharmaceuticals (ACCP), a growing biopharmaceutical company with a focus on oncology, has released financial results for the first quarter of this year, which ended on March 31, 2o13. The Dallas-based company’s lead product, MuGard, has been approved for sale in the United States and Europe, as well as South Korea and China.

http://bionews-tx.com/news/2013/05/21/access-pharmaceuticals-of-dallas-reports-first-quarter-2013-results/

Austin-Based Vermillion Announces First Quarter 2013 Results and Future Plans

Vermillion, Inc. (VRML) has released financial data pertaining to their first quarter results for 2013; these numbers include the results as of March 31, 2013. The company is based in Austin, Texas, and specializes in molecular diagnostics that focus on women’s health and especially gynecological cancers.

http://bionews-tx.com/news/2013/05/16/austin-based-vermillion-announces-first-quarter-2013-results-and-future-plans/

Opexa Therapeutics Reports First Quarter 2013 Financial Results

Opexa Therapeutics (OPXA), a Woodlands-based biotech company specializing in the development of an innovative immunotherapy using T-cells to treat multiple sclerosis, as of April 30, 2013 has enrolled 48 patients with Secondary Progressive Multiple Sclerosis in a Phase IIb clinical test of the imilecleucel-T, autologous T-Cell Immunotherapy known as Tcelna™.

http://bionews-tx.com/news/2013/05/15/opexa-therapeutics-reports-first-quarter-2013-financial-results/

First Quarter 2013 Results Announced for Orthofix International

Orthofix International N.V., a Texas-based company that produces products used to treat spine and orthopedic conditions, has announced their first quarter financial results for 2013.

http://bionews-tx.com/news/2013/05/09/first-quarter-2013-results-announced-for-orthofix-international/